Free Research Reports on These Drug Makers Stocks -- Impax Labs, Merck, Novartis, and Pfizer

Thursday, February 15, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 15, 2018 /PRNewswire/ --WallStEquities.com strives to bring the best free research to the investment community. 

Today we are offering reports on IPXL, MRK, NVS, and PFE which can be accessed for free by signing up to www.wallstequities.com/registration. Today, focus is shifted on the Drugs sector, which is the portion of industry that develops and produces
pharmaceuticals. This sector includes both major corporations and small startup companies that research, create, and manufacture drugs for therapeutic use. Pre-market, WallStEquities.com presents for review four major players in the Drug Manufacturers space, which are: Impax Laboratories Inc. (NASDAQ: IPXL), Merck & Co. Inc. (NYSE: MRK), Novartis AG (NYSE: NVS), and Pfizer Inc. (NYSE: PFE). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Impax Laboratories

On Wednesday, shares in Hayward, California headquartered Impax Laboratories Inc. recorded a trading volume of 396,490 shares. The stock ended at $19.10, rising 1.33% from the last trading session. The Company's shares have gained 10.72% over the previous three months and 35.46% in the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 3.38% and 5.63%, respectively. Furthermore, shares of Impax Labs, which develops, manufactures, and markets bioequivalent pharmaceutical products, have a Relative Strength Index (RSI) of 47.56. Get the full research report on IPXL for free by clicking below at:

www.wallstequities.com/registration/?symbol=IPXL

Merck

Kenilworth, New Jersey headquartered Merck & Co. Inc.'s stock finished yesterday's session flat at $54.90. A total volume of 11.43 million shares was traded. The stock is trading below its 50-day moving average by 4.60%. Furthermore, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 34.40.

On February 14th, 2018, research firm Leerink Partners reiterated its 'Market Perform' rating on the Company's stock with a decrease of the target price from $67 a share to $66 a share. Find your free research report on MRK at:

www.wallstequities.com/registration/?symbol=MRK

Novartis

At the close of trading on Wednesday, shares in Basel, Switzerland headquartered Novartis AG saw a rise of 2.30%, ending the day at $85.52. The stock recorded a trading volume of 1.75 million shares, which was higher than its three months average volume of 1.44 million shares. The Company's shares have advanced 13.78% over the last twelve months. The stock is trading above its 200-day moving average by 1.80%. Moreover, shares of Novartis, which researches, develops, manufactures, and markets a range of healthcare products worldwide, have an RSI of 46.84.

On January 25th, 2018, research firm Leerink Partners reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $93 a share to $100 a share. Sign up today for the free research report on NVS at:

www.wallstequities.com/registration/?symbol=NVS

Pfizer

New York headquartered Pfizer Inc.'s shares ended the day 0.72% higher at $35.19 with a total trading volume of 23.22 million shares, which was above their three months average of 20.61 million shares. The stock has gained 7.45% over the last twelve months. The Company's shares are trading above their 200-day moving average by 1.40%. Additionally, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have an RSI of 43.71.

On January 29th, 2018, research firm SunTrust reiterated its 'Hold' rating on the Company's stock with an increase of the target price from $33 a share to $40 a share. Wall St. Equities' research coverage also includes the downloadable free report on PFE at:

www.wallstequities.com/registration/?symbol=PFE

--

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/free-research-reports-on-these-drug-makers-stocks----impax-labs-merck-novartis-and-pfizer-300599339.html

SOURCE Wall St. Equities

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store